ReGelTec

ReGelTec is pioneering a next-generation, minimally invasive solution for the massive problem of degenerative disc disease (DDD). Its lead product, the HYDRAFIL System, is a proprietary hydrogel that is injected as a liquid through a needle and solidifies in the disc nucleus to mimic natural biomechanics. The company has achieved significant milestones, including CE Mark approval in Europe and the initiation of a pivotal FDA IDE study in the US, supported by strong 1- and 2-year clinical data showing significant reductions in pain and disability. With an experienced leadership team and a technology that addresses a key unmet need between conservative care and major surgery, ReGelTec is positioned as a compelling player in the spinal intervention market.

Proprietary thermosensitive hydrogel (HYDRAFIL) that is injected as a liquid through a needle and solidifies in situ to form a permanent, integrated implant for disc augmentation.

ReGelTec competes in the minimally invasive spine intervention space, facing competition from other nucleus augmentation devices, interspinous process spacers, and biological injections. Its primary competition, however, remains the entrenched standard of care: spinal fusion and artificial disc replacement surgeries offered by large medtech companies, as well as continued conservative pain management techniques.